loading
Jade Biosciences Inc stock is traded at $12.48, with a volume of 235.23K. It is up +24.80% in the last 24 hours and up +0.00% over the past month. Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$10.00
Open:
$10.18
24h Volume:
235.23K
Relative Volume:
34.07
Market Cap:
$533.36M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$9.6601
$13.47
1-Week Range:
Value
$9.02
$13.47
52-Week Range:
Value
$9.02
$13.47

Jade Biosciences Inc Stock (JBIO) Company Profile

Name
Name
Jade Biosciences Inc
Name
Phone
617-443-2400
Name
Address
930 WINTER STREET, WALTHAM
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
JBIO's Discussions on Twitter

Compare JBIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
JBIO
Jade Biosciences Inc
12.48 533.36M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-18-24 Downgrade Evercore ISI Outperform → In-line
Jun-18-24 Downgrade TD Cowen Buy → Hold
Jun-18-24 Downgrade Wells Fargo Overweight → Equal Weight
Jun-17-24 Downgrade BTIG Research Buy → Neutral
Jun-17-24 Downgrade Guggenheim Buy → Neutral
Jun-17-24 Downgrade Wedbush Outperform → Neutral
Mar-25-24 Resumed Jefferies Buy
Dec-08-23 Initiated Wells Fargo Equal Weight
Mar-01-23 Initiated Guggenheim Buy
Dec-06-22 Upgrade BTIG Research Neutral → Buy
Sep-19-22 Resumed Wedbush Outperform
Aug-16-22 Downgrade BTIG Research Buy → Neutral
Feb-11-22 Initiated BTIG Research Buy
Jul-26-21 Initiated Cowen Outperform
Jul-26-21 Initiated Evercore ISI Outperform
Jul-26-21 Initiated Jefferies Buy
Jul-26-21 Initiated Wedbush Outperform
View All

Jade Biosciences Inc Stock (JBIO) Financials Data

There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Cap:     |  Volume (24h):